Navigation Links
PharmAthene to Delay Release of Full Year 2007 Financial Results
Date:3/20/2008

ANNAPOLIS, Md., March 20 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, today reported the company will delay its earnings release for the full year ended December 31, 2007. The earnings release was previously scheduled for today, March 20, 2008. PharmAthene will schedule the new date and time of its earnings release and conference call at a later time.

The conference call originally scheduled to discuss earnings will occur at 4:30 pm E.T. today and will focus on the Avecia acquisition announced earlier today.

About PharmAthene, Inc.

PharmAthene (Amex: PIP) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia(R) for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit http://www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
2. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
3. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
4. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
7. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
10. Flurizans Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimers Disease is Superior to That of Aricept
11. Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... (PRWEB) , ... May 05, 2016 , ... ... is proud to support the National Stroke Association during National Stroke Awareness Month ... association’s Facebook and Twitter pages throughout the month. CereScan will donate $1 ...
(Date:5/4/2016)... , May 4, 2016  Bayer today announced ... compound Stivarga ® (regorafenib) tablets for the ... has met its primary endpoint of a statistically ... RESORCE, evaluated the efficacy and safety of regorafenib ... after treatment with sorafenib. The safety and tolerability ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... PBI-Gordon Corporation ... and Agricultural Sales. , Doug began his career at PBI-Gordon in February 1988, ... in a wide variety of roles, ranging from customer service to national product manager, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Morf Media ... compliance training platform on mobile devices, today released a new interactive Food ... Medical Devices. The course is essential for owners or operators of places of ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):